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Abstract
Antibiotic resistance is increasing in pathogenic microbial populations and is
thus a major threat to public health. The fate of a resistance mutation in patho-
gen populations is determined in part by its fitness. Mutations that suffer little or
no fitness cost are more likely to persist in the absence of antibiotic treatment. In
this review, we performed a meta-analysis to investigate the fitness costs associ-
ated with single mutational events that confer resistance. Generally, these muta-
tions were costly, although several drug classes and species of bacteria on average
did not show a cost. Further investigations into the rate and fitness values of
compensatory mutations that alleviate the costs of resistance will help us to better
understand both the emergence and management of antibiotic resistance in clini-
cal settings.
Introduction
The initial optimism accompanying the introduction of
antibiotics to control infection over 60 years ago has been
steadily worn down by continuing reports of antimicrobial
resistance (AMR) among nearly all human-associated
pathogens (Palumbi 2001; Perron et al. 2006). AMR
already represents a major burden on healthcare systems
around the world. Estimates of the economic burden of
AMR are estimated to be at least 1.5 billion euros annually
in Europe (World Health Organization 2012) and on the
order of $200 million annually in Canada alone (Conly
2002), and these costs are expected to get worse with time.
Widespread therapeutic and prophylactic use of antibiot-
ics in health care and agriculture constitutes a strong and
persistent selective pressure favoring the evolution of anti-
biotic-resistant strains, a phenomenon characterized by
Hall (2004) as ‘use it and lose it’. For this reason, research
has been increasingly focused on eliminating, or at least
controlling, AMR once it has evolved. The most common
strategy is to stop using antibiotics, the assumption being
that mutations conferring resistance impose a large fitness
cost in the absence of the drug. Note that fitness is taken
here to be the rate of replication under prevailing environ-
mental conditions and can be measured through competi-
tive fitness trials or as the growth rate of the strain or
population being considered. Sensitive genotypes that do
not pay a cost of resistance should therefore replace resis-
tant strains at a rate proportional to the magnitude of the
cost imposed by resistance (Levin et al. 1997; Johnsen et al.
2009).
Resistance mutations may be expected to impart a fitness
cost because they target important biological functions in
the cell (Table 1). For example, resistance to fluoroquinol-
ones in pseudomonads can cause impaired motility (Stick-
land et al. 2010), and resistance to aminoglycosides can
alter the structure of the ribosome (Springer et al. 2001;
Holberger and Hayes 2009) and so interfere with basic cel-
lular functions.
Clinical and epidemiological evidence on the effective-
ness of stopping antibiotic treatment as a strategy for
reducing resistance is both limited and mixed. Clinical
studies have shown that in some cases, resistant bacteria
remained abundant in the population (Enne et al. 2001;
Sundqvist et al. 2010) or even increased in frequency (Ara-
son et al. 2002) despite the absence of drug, while in others
the proportion of resistant bacteria within the population
declined (Seppala et al. 1997; Austin et al. 1999; Bergman
et al. 2004; Gottesman et al. 2009), as expected. In epide-
miological studies, reducing the use of antibiotics often
leads to a reduction in the frequency of resistant strains,
but it rarely succeeds in eliminating them altogether (Sal-
yers and Amabile-Cuevas 1997; Andersson 2003; Enne
2010; Johnsen et al. 2011).
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Evidently, the strategy of stopping the use of a drug once
resistance has evolved is not always effective at eliminating
resistance. The question is why? Three hypotheses could
account for the persistence of AMR strains in the absence
of antibiotic (Box 1; Andersson 2003; Andersson and
Hughes 2010). First, genetic linkage between the resistance
gene(s) of interest and selected loci may lead to genetic co-
selection (Borrell et al. 2013) and prevent the elimination
of resistance. Many instances of persistence in multidrug-
resistant strains or plasmid-mediated resistance are likely
due to this mechanism. Second, the fitness costs incurred
by resistance mutations may be compensated by second-
site mutations that increase fitness without compromising
resistance. Such compensatory evolution has been observed
in both in vitro (Levin et al. 2000), in vivo (Bj€orkman et al.
2000), and in clinical studies (Bj€orkholm et al. 2001; Na-
gaev et al. 2001; Gagneux et al. 2006; Comas et al. 2011).
Third, the pleiotropic costs of resistance among mutations
may be so highly variable as to sometimes include ‘no-cost’
mutations (Sander et al. 2002; Ramadhan and Hegedus
2005), those that have fitness indistinguishable from (or
even greater than) their antibiotic-sensitive ancestor in the
absence of antibiotic. This last hypothesis has proven chal-
lenging to evaluate because we know very little about varia-
tion in costs of resistance among different genetic targets.
Previous work has shown that costs of resistance among
single-step, chromosomal mutations can be highly variable
(Kassen and Bataillon 2006), and the literature contains a
number of reports of putatively cost-free mutations,
including streptomycin resistance in the rpsL locus of
Mycobacterium smegmatis (Sander et al. 2002), isoniazid
resistance in katG of Mycobacterium tuberculosis using a
mouse model (Pym et al. 2002) and quinolone resistance
in gyrA and parC of Streptococcus pneumoniae (Gillespie
et al. 2002).
Box 1:Mechanisms of gaining and maintaining antibi-
otic resistance
Prokaryotic microbes can gain resistance de novo by adaptive
evolution or via horizontal gene transfer of resistance cas-
settes between microbes. Resistance can be maintained, in
the absence of antibiotic selection, in three ways. Resistance
mutations may incur no fitness costs and thus remain in the
population in the absence of antibiotic selection pressure.
Alternately, costs of resistance can be compensated via sec-
ond-site mutations that restore organismal fitness in the
absence of antibiotic selection. Finally, genetic co-selection
can occur whereby there is a genetic linkage between a resis-
tance-conferring gene and either other selected genetic
markers or other selected resistance mutations to different
antibiotics, thereby enabling nonselected resistance to remain
within the population.
To explore the nature of the variation in fitness costs
among resistance mutations in more detail, we collate data
from the literature on the fitness effects of single chromo-
Table 1. Antibiotics included in this meta-analysis
Antibiotic class
Examples of antibiotics
(included in this study) Mode of action (Target) Mechanisms of resistance
Known genes involved
in mutations conferring
resistance
Alpha-pyrone Myxopyronin RNA replication: inhibits bacterial
RNA polymerase (RNAP)
Altered target rpoB, rpoC
Aminoglycoside Amikacin, streptomycin,
spectinomycin
Protein synthesis: binds to 30S
subunit bacterial ribosome
inhibiting translation
Drug efflux, altered target,
enzymatic inhibition of drug
rpsL, rrs, rrl, rpsE
Coumarin Coumermycin, novobiocin DNA replication: inhibits DNA
gyrase and topoisomerase IV enzyme
Drug efflux, altered target gyrB
Dihydrofolate
reductase
inhibitor
Trimethoprim DNA replication: blocks the folate
coenzyme biosynthetic pathway,
essential for providing monomers
for DNA synthesis
Decrease thymidine
requirement, altered target
dfrA
Fusidane Fusidic acid Protein synthesis: prevents the turnover
of elongation factor G from the ribosome
Drug efflux, mutations
in elongation factor G
fusA
Macrolide Clarithromycin,
erythromycin,
tylosin
Protein synthesis: binds to 50S subunit
bacterial ribosome inhibiting translation
Drug efflux, altered
drug target,
inactivation of drug
23S rRNA genes
Quinolone Ciprofloxacin, nalidixic
acid, norfloxacin
DNA replication: inhibits bacterial
DNA gyrase and topoisomerase IV enzyme
Drug efflux, altered target gyrA, gyrB, parC,
parE, grlA
Rifamycin Rifampicin RNA replication: binds to RNA polymerase Altered target rpoB
Andersson and Hughes (2010); Bryskier (2005); Davies and Davies (2010); Walsh (2003).
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somal mutational events that confer antibiotic resistance
from a wide range of pathogenic bacterial species. Our
objective is to examine the prevalence of so-called ‘no-cost’
resistance mutations with the aim of evaluating whether
these could make a substantial contribution to the persis-
tence of AMR (Box 2). We focus on studies that measure
fitness directly through competitive assays between a strain
with a resistance mutation and the isogenic strain lacking
that mutation. This method is preferred over alternatives
such as the measurement of population growth rates in
pure culture because it is an integrated measure involving
all phases of the growth cycle and can capture aspects of
competition such as toxin production that may not be
reflected in pure culture assays.
Box 2: Glossary
Compensatory mutation: A second-site mutation that occurs
after a mutation that confers resistance, which lessens or alle-
viates the fitness costs associated with resistance.
Cross-resistance: The propensity of a genetic change that
confers resistance to one drug also to affect resistance to a dif-
ferent drug (by either increasing or decreasing resistance).
Epistasis: When the fitness effect of a mutation is modu-
lated by its interactions with other genes or mutations in the
genome.
Genetic co-selection: The occurrence of genetic linkage
between the resistance-conferring gene and other selected
genetic markers. Thus, even though a nonselected resistance
gene might confer a cost, it could remain in the population
because of its genetic linkage to a second marker.
Genetic plasticity: The alterable nature of prokaryotic ge-
nomes that enables the fluid exchange of DNA from one
microorganism to another.
Horizontal gene transfer: The acquisition of a gene by a
means other than direct inheritance from a parent cell (vertical
transfer). Common in many bacteria and archaea, mecha-
nisms of horizontal gene transfer include transformation, con-
jugation, and transduction.
Minimum inhibitory concentration: The lowest concentra-
tion of an antibiotic that will inhibit the visible growth of a
microorganism after overnight incubation.
Relative fitness: the capability of a genotype or individual to
survive and reproduce in comparison with a second genotype
or individual.
Previous work has highlighted the potential importance
of no-cost resistance mutations, and the variation in costs
of resistance more generally, in pathogenic bacteria
(Andersson 2003, 2006; Andersson and Hughes 2010). To
our knowledge, no formal meta-analysis on the relative
costs of antibiotic resistance mutations has been per-
formed. In this article, we analyze 179 mutations (121
unique), comprising eight bacterial species and 16 antibiot-
ics, and address the following questions: Are certain antibi-
otics or species more likely to be associated with no-cost
resistance? If so, why? Is there a correlation between the
magnitude of the fitness cost and the level of resistance
conferred by a given mutation? If higher levels of resistance
require a cell to devote more resources to detoxifying or
eliminating a drug or involve mutations of greater pheno-
typic effect, we might expect a negative relationship
between MIC and fitness. However, this hypothesis has
rarely been tested directly. Answering these questions pro-
vides a glimpse into some of the most basic patterns associ-
ated with resistance mutations and their effects on fitness, a
subject that has received surprisingly little direct attention
in the literature.
Methods
We identified suitable studies to include in our data set by
searching the online database Web of Science with the key-
words ‘antibiotic resistance’ + ‘fitness cost’ published as of
November 2013. Additional studies were found by search-
ing the reference sections of these articles. Many studies
could not be included because fitness was measured as the
growth rate of each strain rather than via competitive fit-
ness assays.
The principle behind a competitive fitness assay is that a
fitter type will outcompete a less fit type when co-cultured
in the same set of growth conditions. The rate at which one
type excludes the other is a measure of its fitness. Estimat-
ing competitive fitness requires monitoring the change in
relative frequencies of otherwise isogenic sensitive and
resistant strains over time. Different research groups use
slightly different methods to calculate fitness, so here we
have recalculated all fitness estimates in terms of the Mal-
thusian growth parameter to facilitate direct comparisons
(see Box 3).
To be included in our database, an article had to satisfy
strict selection criteria: (i) data needed to include an esti-
mate of both mean and variance of competitive fitness, (ii)
competitive fitness had to be measured via in vitro assays,
(iii) resistance had to be conferred by a single mutational
event, and (iv) the study needed to be performed in bacte-
ria. We thus rejected many studies that did not include the
relevant measures. Altogether, 24 studies were included in
the analysis comprising 16 antibiotics (Table S1) from eight
antibiotic classes. These studies further included a total of
eight bacterial species (Table S2) including Escherichia coli,
a ubiquitous Gram-negative bacterium, and S. pneumo-
niae, an important Gram-positive opportunistic pathogen.
Four papers were excluded because replicate measures of
fitness were not provided, making it impossible to estimate
the variance in fitness (Billington et al. 1999; Binet and
Maurelli 2005; Enne et al. 2005; Nessar et al. 2011). Four
further papers were excluded because competitive fitness
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was calculated in vivo, which is not a comparable metric to
relative fitness calculated in vitro because it lacks a measure
of generation time (Nagaev et al. 2001; Gustafsson et al.
2003; Luo et al. 2005; Luangtongkum et al. 2012). Two
papers were excluded because relative fitness measures were
illustrated graphically, without providing the numerical
measures necessary for the meta-analysis (Bj€orkholm et al.
2001; Huitric et al. 2010).
Box 3: Estimation of competitive fitness
Competitive assays provide the ‘gold standard’ for measuring
fitness. In its simplest form, a competition experiment allows
for the estimation of fitness for a focal strain (either a single
genotype or a population) relative to a defined, typically ‘wild-
type’ competitor, in a given laboratory environment. The focal
strain and the wild-type competitor need to be readily distin-
guishable, for example, via a phenotypic marker (lacZ+ vs
lacZ, or alternative fluorescent markers) or by genotyping.
To estimate the costs of antibiotic resistance, the competition
environment should be antibiotic-free and is typically a stan-
dard laboratory medium such as Lysogeny Broth (LB). The
focal strain and the wild type are competed together for a fixed
period of time, often 24 h, and samples taken at the beginning
and end of the competition allow the researcher to determine
the number of focal and wild-type cells in the population. Fit-
ness of the focal strain can then be inferred from the change in
its relative abundance: If the focal strain suffers a fitness cost,
then its frequency will decrease.
Several formulae have been proposed for estimating the
selection coefficient on a genotype, s, from competition data
(where relative fitness is given by 1 + s). Lenski et al. (1991)
consider fitness in terms of a Malthusian growth model, where
the growth parameter for a strain is the number of doublings
that it experiences over a given period of time. As such, the
selection coefficient on the focal strain is defined as follows:
sl ¼ No. of doublings of focal strain
No. of doublings of wild - type
 1
Note that sl is a unit less parameter.
Alternatively, Dykhuizen and Hartl (1983) estimate the
selection coefficient as
sd ¼ ðln ðn1f =n1iÞ  ln ðn2f =n2iÞÞ
No. of generations
where n1f and n1i are the number of cells of the focal strain at
the end and the beginning of the assay, and n2f and n2i are the
number of cells of the wild-type strain at the end and the
beginning of the assay. Note that sd has units generations
1.
Both estimates of fitness are widespread in the literature,
and we see no principled reason to prefer one to the other. In
the context of the current meta-analysis, and more broadly, it
is important to know the relationship between these two fit-
ness estimators: To what extent do they agree in terms of the
magnitudes of s? As such, we simulated pair-wise competitions
using a simple growth model, in which each genotype grows
according to a Poisson process. Samples were drawn from the
simulated competition experiments, and sl and sd were esti-
mated from the same data.
Notably, the magnitude of sl is systematically larger than the
magnitude of sd. Figure 1 shows the relationship between sl
and sd for a set of simulations where growth rates of the com-
peting strains varied from 0 to 0.25, with the initial frequency
of the focal strain set to 0.5 and competition carried out over
six generations. Note that there is a tight linear relationship
between sl and sd, with sl exceeding sd by a factor of about 1.7.
The slope of the regression line appears to be insensitive to
starting frequency and is weakly affected by the number of
generations of competition: So long as the competition experi-
ment proceeds for four or more generations, sl exceeds sd by a
factor of 1.7.
Given that competitive fitness is quantified fairly easily
in bacteria and is such an inclusive fitness measure, it
was surprising to us that more studies have not employed
this method. Many other studies investigating costs of
resistance used growth rate as a proxy for fitness, which,
as outlined above, incorporates only a single component
of bacterial fitness. Including growth rate studies would
have increased the sample size of our meta-analysis; how-
ever, the inclusion of such data would reduce the clarity
of the analysis because measures of growth rate and com-
petitive fitness are poorly correlated. To examine this
relationship in more detail for our data set, we examined
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Figure 1 Estimation of selection coefficients using the Lenski and
Dykhuisen estimators. Competition experiments were simulated for
two strains, with the wild-type strain doubling in each time unit, and
the growth rate of the focal strain reduced compared to wild type by
0 to 0.25. Competition lasted six generations, starting with a 50:50
ratio of the two strains and an initial population size of 1 million. Each
data point represents the mean values of s for 100 simulations. For
each replicate, an average of 100 individuals were sampled and used
to calculate sl (y-axis) and sd (x-axis). The dashed line represents a 1:1
relationship, and the solid line gives the linear regression of sl on sd.
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35 mutations that supplied estimates of competitive fit-
ness and for which we could compute a relative doubling
time (Gillespie et al. 2002; Hurdle et al. 2004; Mariam
et al. 2004). The data included 35 different antibiotic
resistance mutations from three different bacterial species
and four different antibiotics. In these studies, competi-
tive fitness and relative doubling time were not correlated
(r2 = 0.00734, P = 0.619). We encourage future studies
investigating costs of resistance mutations to use compet-
itive assays to measure the relative fitness of resistant and
sensitive strains.
For the purposes of this study, we focused on resis-
tance caused by single mutational events. The rationale
behind this is simple: We need to be confident that resis-
tance, and any associated fitness cost, is due to that
mutation only and not other, co-occurring mutations. In
our study, the vast majority of these mutations are single
nucleotide polymorphisms (SNPs) although three small
(3, 9, or 13 nucleotides, respectively) deletions were also
included. All are chromosomal mutations because our
interest is in the effects of these mutations on the fitness
of the bacterial genotype itself, not the fitness of a plas-
mid on which the mutation arises. Thus, we excluded
studies that examined resistance gained by plasmids, hor-
izontal gene transfer, those examining multidrug resis-
tance, and studies which examined the fitness costs of
multiple resistance mutations (Hurdle et al. 2004) within
the same genetic background.
We report measures of drug resistance as the fold-
increase in minimum inhibitory concentration (MIC) rela-
tive to the drug-sensitive ancestor. If absolute drug concen-
tration was reported, then these data were converted to
fold-increase in MIC by dividing the concentration of drug
required to inhibit growth in the resistant strain by the
concentration of drug required to inhibit growth in the
sensitive ancestor. If MICs were reported as a greater than
value, the numerical value itself was recorded.
We analyzed the data set using a random effects meta-
analysis, using the metagen function within the meta pack-
age of R (R Development Core Team 2013; Schwarzer
2013). A random effects model is more appropriate than a
fixed effects model as we cannot be certain that all studies
included in our meta-analysis have equal variances. A rela-
tive fitness value >1 indicates the mutation is both resistant
and beneficial relative to the isogenic strain lacking the
mutation; values <1 indicate the resistant mutation is
costly. We evaluated the statistical significance of our fit-
ness estimates by examining the 95% confidence intervals
of the mean relative fitness. If these did not overlap with
one, the fitness estimate was considered significant. Q-sta-
tistics were used to examine the heterogeneity of relative
fitness values among groups. Each mutational event confer-
ring resistance is taken to be a single unit of analysis, the
rationale being that single mutational events occur inde-
pendently of each other and often in different genetic back-
grounds.
Results
Are there costs of resistance?
We found a significant fitness cost of resistance mutations
(mean fitness = 0.880, z = 129.3, P < 0.0001). The data
exhibited significant total heterogeneity in their response
(Qtotal = 22 966, P < 0.0001), indicating the presence of
further explanatory variables within the data set.
To describe the data in more detail, we plotted the stan-
dard error of mean fitness against mean fitness for all
mutations in our collection (Figure S1). A linear regression
testing for funnel plot asymmetry is significant
(t177 = 4.48, P < 0.001), indicating bias in the data
toward, in this case, costly mutations. The most parsimoni-
ous interpretation is that resistance mutations are often
genuinely costly. It seems unlikely that this result represents
a publication bias because, if anything, the observation of
no-cost mutations is the more novel result. Notably, there
is also substantial variation in costs of resistance with at
least some mutations exhibiting little or no cost.
Variation in costs of resistance
Variation in costs of resistance can arise either because
some mutations are costly and others are not, irrespective
of the genetic background in which they occur, or because
a given mutation is not costly in some genetic backgrounds
but is costly in others. We investigated these alternatives by
repeating our analysis with drug class, drug, or species as
explanatory factors. A main effect of species indicates that
the fitness effect of a given mutation depends on the
genetic background in which it occurs while main effects of
either drug or drug class indicate that the mutations them-
selves differ in their costs, independent of genetic back-
ground. We found evidence to support both explanations.
There was a significant difference in the fitness costs of
resistance mutations between drug classes (Figure S2,
Qbetween = 144, P < 0.0001), between different drugs
(Fig. 2, Qbetween = 282, P < 0.0001), and between different
bacterial species (Fig. 3, Qbetween = 75.5, P < 0.0001). The
mean relative fitness of resistance mutations associated
with each of these different subgroups can be seen in
Figs 2, 3, and S2, respectively. This result must be inter-
preted with caution, however, because the data set is
severely unbalanced. Most resistance mutations are unique
to a particular species and drug. Some of the variation is
likely attributable to a lack of data, for example, there are
only four resistance mutations associated with fusidic acid
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(Table S1), while other sources of variation might be
because there is only a single drug–bacterium comparison
for a given species, for example, all eleven mutations mea-
sured for M. tuberculosis confer resistance to rifampicin
(Table S2). Nevertheless, our data suggest that costs of
resistance can be highly variable and can depend on the
class of drug used, the mutation itself, and the species
within which that resistance mutation occurs.
Notably, some mutations appear to be either genuinely
cost-free or the costs are so small they cannot be detected
in these assays. In our data set, these putatively ‘no-cost’
mutations are associated with resistance to fusidanes and
dihydrofolate reductase inhibitors (Fig. 2, Figure S2). Of
note, the mean fitness of mutations conferring resistance to
the dihydrofolate reductase inhibitor trimethoprim was >1
(Fig. 2), indicating that these resistance mutations are ben-
eficial in the absence of drug. Additionally, resistance
mutations in two species, Enterococcus faecium and Borrelia
burgorferi, showed no evidence for a cost of resistance on
average while those recovered from all other species were
on average costly (Fig. 3). The average fitness of each spe-
cies and antibiotic comparison yielded no clear patterns in
costs of resistance (Fig. 4).
The sparseness of our data set precludes us from doing a
fully factorial analysis of mutations, drugs, and species.
However, we can perform such an analysis for a subset of
our data, namely the resistance mutations associated with
quinolone and rifamycin drug classes for both Staphylococ-
cus aureus and E. coli (Table S3). The simplest meta-analy-
sis shows a significant fitness cost of resistance mutations
(mean fitness = 0.874, z = 64.4, P < 0.0001), with signifi-
cant heterogeneity (Qtotal = 11592, P < 0.0001). The fully
factorial linear model that treats species and drug class as
fixed effects revealed a significant interaction between drug
Rifampicin
Olfloxacin
Norfloxacin
Nalidixic acid
Ciprofloxacin
Tylosin
Erthyromycin
Clarithromycin
Fusidic acid
Trimethorprim
Novobiocin
Coumermycin
Streptomycin
Amikacin
Spectinomycin
Myxopyronin
0.5 0.6 0.7 0.8 0.9 1.0 1.1
Fitness
Figure 2 The mean relative fitness and 95% confidence intervals of
antibiotic resistance mutations associated with a given antibiotic,
grouped by class of antibiotic (from top to bottom alpha-pyrone, ami-
noglycoside, coumarin, dihydrofolate reductase inhibitor, fusidane,
macrolide, quinolone and rifamycin). A fitness value of <1 indicates a
fitness cost in the absence of the antibiotic.
B. burgdorferi
C. jejuni
E. coli
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M. smegmatis
M. tuberculosis
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S. pneumoniae
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Figure 3 The mean relative fitness and 95% confidence intervals of
antibiotic resistance mutations associated with a given species. A fitness
value of <1 indicates a fitness cost in the absence of the antibiotic.
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Figure 4 Species–antibiotic comparisons of the mean relative fitness of
resistance mutations in the absence of the antibiotic. Numbers indicate
antibiotic class: 1 – alpha-pyrone, 2 – aminoglycoside, 3 – coumarin, 4 –
dihydrofolate reductase inhibitor (DHRI), 5 – fusidane, 6 – macrolide,
7 – quinolone and 8 – rifamycin.
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class and species (F3,80 = 14.5, P < 0.0001), but no signifi-
cant differences associated with the main effect of species
or drug class. While this result is based on a limited data
set, it does lend support to the idea that the fitness effect of
resistance mutations in the absence of drugs depends on
both the drug class and the genetic background in which
those mutations appear.
The cell wall is an important target of mutations that
confer antibiotic resistance, and thus intuitively, it seems
possible that there may be a difference in fitness costs asso-
ciated with antibiotic resistance between Gram-positive,
which has a much thicker layer of peptidoglycan in their
cell wall, and Gram-negative bacteria, which has a much
thinner cell wall. Gram-positive bacteria had a significantly
greater fitness costs associated with resistance mutations
(mean fitness = 0.822) when compared with Gram-nega-
tive bacteria (mean fitness = 0.973, t156 = 5.19,
P < 0.0001). Again, caution must be used in interpreting
this result because there were a greater number of Gram-
negative than Gram-positive bacteria in our data set.
The relationship between MIC and cost of resistance
We regressed MIC against relative fitness to test the predic-
tion that high levels of resistance impose greater fitness
costs than lower levels of resistance (Fig. 5). The relative
fitness of a resistance mutation is negatively correlated with
the fold-increase in MIC conferred by the mutation (Fig. 5,
t126 = 6.21, P < 0.0001), with fold-increase in MIC
accounting for 22.8% of the variation in fitness
(F1,126 = 38.6, P < 0.0001). A subset of data was used for
this analysis because seven studies did not measure MIC
(Schrag and Perott 1996; Criswell et al. 2006; Gagneux
et al. 2006; Balsalobre and de la Campa 2008; Hao et al.
2009; Trindade et al. 2009; Borrell et al. 2013). Although it
would be of interest to perform separate regressions for
each class of antibiotic to see if the correlation holds across
different mechanisms of action, for many of the drug clas-
ses, sample sizes are too small to permit reliable regression
coefficients to be estimated.
Discussion
Using meta-analysis, we have found that most resistance
mutations in bacteria confer a fitness cost. This result is not
surprising as many antibiotics target important cellular
processes and resistance to them either disrupts those pro-
cesses or imposes large energetic burdens that reduce com-
petitive ability against sensitive strains. However, we have
also found that there is substantial variation in fitness costs
among species and drugs. This variation is large enough to
include, occasionally, what might be classified as no-cost
resistance mutations. This class of resistance mutation is
not common, at least in our data set, and the actual cost
associated with a particular mutation can depend on the
genotype in which the mutation occurs. Costs will also
likely depend on the environment in which the genotype is
growing due to variation in resource identity and abun-
dance, as well as the general level of stress imposed on the
cell. We cannot examine this hypothesis in more detail,
unfortunately, as the appropriate data are not available.
Furthermore, we know little about how well measures of
costs in vitro correlate to those incurred in vivo. Neverthe-
less based on the available data we do have, we conclude
that no-cost resistance mutations are likely not major con-
tributors to persistent drug resistance in the absence of
antibiotic.
Can we move from a phenomenological description of
the variation in costs to a more mechanistic interpretation?
Why, for example, are resistance mutations costly in some
situations and not in others? Clearly, epistasis can play a
role. In an evolutionary context, epistasis refers to a situa-
tion in which the fitness effect of a mutation depends on its
genetic background. For example, ciprofloxacin resistance
in Campylobacter jejuni is often via mutations in gyrA,
which encodes a DNA gyrase. In one case, a resistance
mutation (C257T) that showed a fitness benefit in one
strain of C. jejuni was costly in another strain (Luo et al.
2005). Environment can also be important. The fitness esti-
mates we examined here are all obtained in vitro and may
not always reflect key aspects of fitness in vivo. Indeed, at
least two resistance mutations in fusA that each confer
resistance to fusidic acid in Salmonella typhimurium
(Macvanin et al. 2003, 2004) and two mutations in rpoB
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Figure 5 The level of resistance conferred by a mutation is negatively
correlated with its’ fitness in the absence of the antibiotic (r2 = 0.228).
Different symbols are associated with different classes of antibiotic.
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(S464P and S531L) conferring rifampicin resistance in
S. aureus show evidence that fitness costs change depend-
ing on whether it is measured in vitro or in vivo (Yu et al.
2005; Gagneux et al. 2006).
Further generalizations are difficult because our data set
is quite sparse. Most of the fitness estimates for a given
mutation are gathered in single environments, which
makes generalization difficult. Moreover, the fitness cost of
the same resistance mutation is rarely assayed in more than
one strain, let alone more than one species. Thus, our abil-
ity to draw strong inferences on the causes of such varia-
tion in costs of resistance remains limited.
Nevertheless, at least two results appear noteworthy and
warrant further investigation. The first is that there is fairly
good evidence that mutations that confer larger MICs are
more costly. This result is in line with previous studies that
found a similar relationship between MIC and growth rate
(Ender et al. 2004; Hurdle et al. 2004). It has also been
shown that the first mutations that arise and confer resis-
tance to ciprofloxacin in Pseudomonas aeruginosa are gen-
erally costly (Wong et al. 2012). This relationship can be
understood very generally in terms of Fisher’s geometric
model of adaptation: Mutations of large effect for one phe-
notype (MIC) have pleiotropic effects on other phenotypes,
the result being that an individual is knocked off a local fit-
ness peak. More mechanistically, the causes of pleiotropy
due to resistance mutations stem either from the fact that
dealing with high levels of toxin in the environment is an
energetically costly process that takes resources away from
other cellular functions, or because resistance is gained via
mutations that alter or disrupt enzyme function and the
production of essential proteins.
The second notable result is that the presence of a
thicker cell wall, one of the defining features of Gram-
positive bacteria, is associated with larger fitness costs.
While this result must be interpreted with caution
because it is based on few data points, it is interesting
that it holds for many different kinds of resistance muta-
tion, including those that confer resistance through both
small molecule efflux and target binding. It thus appears
to be a very general result although the biological reason
for this remains unclear. One, rather simplistic, sugges-
tion is that the presence of a cell wall imposes an addi-
tional energetic burden on toxin clearance that Gram-
negative bacteria do not have to deal with.
The main clinical implication of this work is that no-cost
mutations are probably not a common reason why antibi-
otic resistance persists in the absence of drug use. Rather, it
seems much more likely that persistence is due either to
co-selection of genetically linked mutations or because the
fitness cost of resistance mutations is often compensated by
mutations elsewhere in the genome. Indeed, previous work
suggests that compensatory mutations can arise within a
few generations following the emergence of resistance
(Bj€orkman et al. 2000; Maisnier-Patin et al. 2002; Kugel-
berg et al. 2005; Paulander et al. 2007; Bataillon et al.
2011; Sousa et al. 2012; Wong et al. 2012; de Vos et al.
2013). Furthermore, the presence of additional resistance
mutations can compensate for the cost of an initial resis-
tance mutation, a form of positive epistasis for fitness
(Trindade et al. 2009).
That said there is some evidence that resistance muta-
tions with low or no fitness costs can be prevalent in clini-
cal populations. For example, the spectrum of mutations in
rpoB that cause rifampicin resistance in clinical isolates of
M. tuberculosis and S. aureus is biased in favor of low-cost
mutations (O’Sullivan et al. 2005; O’Neill et al. 2006). The
K424R substitution in the 30S ribosomal protein S12 also
does not exhibit a fitness cost associated with resistance in
both S. typhimurium and M. smegmatis, and this same
mutation is also primarily responsible for resistance to
streptomycin in clinical isolates of M. tuberculosis (B€ottger
et al. 1998; Sander et al. 2002). Other mutations in rpoB
can be costly, as evidenced by the fact that putative com-
pensatory mutations in rpoA and rpoC are routinely iso-
lated alongside some resistance-causing rpoB mutations
(Comas et al. 2011). Thus, while no-cost mutations may
not be a general explanation for why antibiotic resistance
persists in the absence of drug, it may be important in spe-
cific cases.
Taken together, these observations suggest that no-cost
mutations cannot be automatically dismissed as an expla-
nation for why antibiotic resistance persists in clinical
settings even after the offending drug is removed from
use. Whether costs of resistance are an effective guide to
predicting the prevalence of resistance following reduced
drug prescription remains an open question. Enne (2010)
investigated this question directly and found mixed
results, with reduced prescriptions leading to reduced
prevalence in some cases but not others. Notably, in two
cases where our results indicate a significant cost of resis-
tance for a given bacterial species, Enne also found that
prevalence was reduced following prescription reduction
of penicillin for S. pneumoniae (Austin et al. 1999) and
quinolones for E. coli (Gottesman et al. 2009), lending
some support to the predictive ability of costs of resis-
tance from individual mutations. However, other exam-
ples show contrasting results. For example, persistent
quinolone resistant E. coli was found in a remote com-
munity where quinolones were not prescribed (Pallecchi
et al. 2012), suggesting co-selection. It has been suggested
that, in the case of quinolone resistance in this species,
co-selection could occur because resistance can be plas-
mid-mediated (Wang et al. 2003).
The take-home message here is that there may not be
any simple connection between the cost of resistance for
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individual mutations and clinical prevalence of resistance.
Given the variety of factors that can modulate costs – epis-
tasis between the resistance mutation and genetic back-
ground or even other resistance mutations, the
environment, the occurrence of compensatory mutations,
and genetic linkage between the resistance mutation and
other mutations under selection – this should not be sur-
prising. The evolution of costs of resistance and its connec-
tion to clinical treatment is a more complex issue than was
initially thought. Future work should focus on disentan-
gling the contributions of these various factors, in particu-
lar compensatory mutations that seem to evolve very
quickly alongside costly resistance mutations, to the persis-
tence of antibiotic-resistant strains in clinical and environ-
mental settings.
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